Alnylam Pharmaceuticals, Inc. (ALNY) is a global, leading biopharmaceutical company that specializes in discovering, developing, and commercializing RNA interference (RNAi) therapeutics.
Founded in 2002 in Cambridge, Massachusetts, the company was established with a bold vision to harness the potential of RNAi therapeutics. The inspiration for Alnylam's name came from the brightest star in the constellation, Lyra, symbolizing their commitment to scientifically innovative approaches and novel therapies.
RNAi is a natural cellular process of gene silencing, exploiting the body's own natural processes to prevent the production of specific proteins that contribute to various diseases. Alnylam's advancement and dedication in harnessing this cutting-edge science have put them at the forefront of the RNAi therapeutics industry.
Since its inception, Alnylam has remained committed to a patient-focused mission. This is evident in their diverse and robust pipeline of investigational medicines in both clinical and pre-clinical stages targeting severe and life-threatening diseases. These include rare genetic, cardio-metabolic, hepatic infectious, central nervous system (CNS), and ocular diseases.
Alnylam's pioneering work has led to the approval and marketing of ONPATTRO (patisiran), the world's first approved treatment for hATTR amyloidosis in adults. This achievement puts the company on the map as one of those that translated the Nobel Prize-winning science into an approved treatment, ushering in a new class of innovative medicines.
In their quest for scientific innovation, Alnylam also maintains strong collaborations with leading global pharmaceutical and life science companies, such as Sanofi Genzyme, Regeneron, and The Medicines Company. Through these strategic partnerships, the company aims to broaden the global reach of its RNAi therapeutics.
Alnylam Pharmaceuticals, Inc., although a publicly traded company (NASDAQ: ALNY), remains dedicated to its initial vision for scientific innovation, patient-focused drug development, and building an industry-leading pipeline of transformative RNAi-based medicines. Its more than 800-strong global workforce is driven by an unwavering commitment to patients in urgent need of treatments, reflecting the company's overarching dedication to the advancement of human health.